Regenxbio (RGNX) Soars 5.4%: Is Further Upside Left in the Stock?

Company Overview - Regenxbio (RGNX) shares increased by 5.4% to close at $11.6, following a notable trading volume, despite a 23.5% loss over the past four weeks [1] - The stock's rebound is attributed to a market correction after a steep selloff due to the FDA's clinical hold on its gene therapy RGX-111 for MPS I and RGX-121 for MPS II, following a case of neoplasm in a patient [2] Financial Performance - Regenxbio is expected to report a quarterly loss of $0.99 per share, reflecting a year-over-year change of +2%, with revenues projected at $31.49 million, an increase of 48.5% from the previous year [3] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating a lack of upward trend in earnings estimate revisions [4] Industry Context - Regenxbio is part of the Zacks Medical - Biomedical and Genetics industry, where another company, CytomX Therapeutics (CTMX), experienced a 2.7% decline to $5.74, despite a 38.5% return over the past month [4] - CytomX Therapeutics' consensus EPS estimate has decreased by 0.5% to -$0.08, representing a significant year-over-year change of -136.4% [5]